Ef fi cacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
University of California, Los Angeles, California, USA Charité—University Medicine Berlin, Berlin, Germany Rheumatology Research Unit, Nambour Hospital, Sunshine Coast, Australia Department of Medicine, University of Queensland, Queensland, Australia Centro Paulista de Investigação Clinica, São Paulo, Brazil Pfizer Inc, Groton, Connecticut, USA Pfizer Inc, New York, New York, USA Pfizer Inc, Collegeville, Pennsylvania, USA Department of Medicine, Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA